ArQule, Inc.
Clinical trials sponsored by ArQule, Inc., explained in plain language.
Now part of
Merck & Co., Inc.
MRK
NYSE
Biopharmaceutical company focused on targeted cancer therapies, now a subsidiary of Merck.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for Hard-to-Treat blood cancers Results expected Sep 2027 (estimated)